33
Participants
Start Date
June 30, 2010
Primary Completion Date
December 31, 2016
Study Completion Date
March 31, 2017
Docetaxel, Cisplatin, 5-FU and Cetuximab
"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
Department of Clinical Oncology, Queen Mary Hospital(QMH), Hong Kong, Hong Kong
Department of Clinical Oncology, Queen Mary Hospital, Hong Kong
Department of Clinical Oncology, Tuen Mun Hospital (TMH), Hong Kong, Hong Kong
Department of Oncology, Princess Margaret Hospital, Hong Kong
Collaborators (1)
The University of Hong Kong
OTHER
Sanofi
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Roche Pharma AG
INDUSTRY
Hong Kong Nasopharyngeal Cancer Study Group Limited
OTHER